Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia

Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Feb 17, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how some patients with chronic lymphocytic leukemia (CLL) develop resistance to a treatment called venetoclax. Researchers want to collect medical information and samples from patients whose CLL has returned or who have not responded well to venetoclax treatment. By doing this, they hope to understand how often resistance happens and what causes it.

To participate in this study, you must be at least 18 years old and have a diagnosis of chronic lymphocytic leukemia. You should also have experienced a return of your disease or a lack of response to venetoclax treatment. If you decide to join, you will provide tumor samples and information about your health. It's important to know that participation is completely voluntary, and you can choose not to take part if you prefer. This study is currently looking for participants, and you will be helping researchers learn more about CLL and how to improve treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age greater than or equal to 18 years old;
• • chronic lymphocytic leukemia diagnosis according to iwCLL criteria;
• • refractory and/or relapsed disease during or after venetoclax treatment;
• • tumor samples available.
• • Relapse might be progressive chronic lymphocytic leukemia or transformation into Richter syndrome.
• • Patients must be able to express their opposition to be enrolled in this study, if need be.
• • Patients must be affiliated at the French Social Security system
• Exclusion Criteria:
• • Patients of their legal guardians refusing to participate
• • -